Therefore, the use of a potent multikinase inhibitor, such as sorafenib, could limit the proliferative, proangiogenic, and/or antiapoptopic effects of VEGF expression, which could restrict tumor growth after TACE (12). The gene discussed is VEGFA; the disease is neoplasm.